Relmada Therapeutics (RLMD) Tops Q4 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies